SUN VIZEN

SunVizen is a biotechnology company focused on developing next-generation gene therapies for ophthalmic conditions. As a specialized venture of Sun Pharmaceutical Industries, the company leverages adeno-associated virus (AAV) platforms to target retinal diseases such as geographic atrophy secondary to age-related macular degeneration. Their lead programs aim to address significant unmet needs in vision loss through innovative molecular approaches designed for long-term efficacy. SunVizen operates at the intersection of advanced genetic medicine and established pharmaceutical expertise to accelerate the delivery of sight-saving treatments. The company is currently advancing its lead candidate, SVZ-101, through preclinical development with the goal of providing a durable therapeutic option via a single administration.